Table 1.

Patients with ovarian cancer and presence of Yo antibodies and CDR2 mRNA and protein

Patient no.	Age (years)	Histology (adenocarcinoma)	FIGO stage	Yo antibody	CDR2 mRNA	CDR2 protein
1	78	Endometrioid	III	+	+	+
2	55	Serous	III	−	+	+
3	57	Serous	III	−	+	+
4	53	Mucinous/borderline	III	−	+	+
5	64	Serous	III	−	+	+
6	69	Undifferentiated	III	−	+	+
7	58	Serous	IV	+	+	+
8	78	Serous	IV	−	+	+
9	56	Serous	III	−	+	+
10	48	Endometrioid	III	−	+	+
11	62	Endometrioid	III	+	+	+
12	79	Mucinous	I	−	+	+
13	41	Mucinous/borderline	I	−	+	+
14	55	Clear cell	I	−	+	+
15a	60	Serous	III	+	ND	+
16a	58	Serous	IV	+	ND	+

^aPatients with paraneoplastic cerebellar degeneration; CDR2 cerebellar degeneration-related protein 2; FIGO International Federation of Gynecology and Obstetrics